COMPANY PROFILE · /exscientia
E
Exscientia
Pioneering AI-driven drug discovery platform integrating computational design with human expertise to accelerate development of tailored therapeutics. Platform (Centaur Chemist) identifies drug targets, designs molecules, and advances candidates to clinical trials through precision medicine approach.
Fresh · 5d ago
Latest valuation
—
Annual Recurring Revenue
—
Headcount
—
Funding total
$200M+
OVERVIEW
Acquired by Recursion Pharmaceuticals (late 2024) for significant consideration; has multiple clinical candidates in oncology and immunology; exemplar of patient-centric AI drug design; now integrated into Recursion's dual-model (platform + asset) strategy.
Status
active
Tier
master-list
Profitability
—
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0
No products catalogued yet. Press Refresh above to ask the research agent.
TEAM · 0 key people
No people linked.
SOURCES · 0 cited
No citations stored yet. Run the research agent to attach per-claim sources.